Novo Nordisk has unveiled plans to make a DKr15.9bn ($2.29bn) investment, starting from 2023, to expand its manufacturing facilities in Hillerød, Denmark.
The new investment will create additional production capacity, increase the company’s capacity to meet future demand and enable the development of its future clinical late-phase product portfolio.
The investment will be used for expanding its existing Danish active pharmaceutical ingredient (API) production facility to progress its future serious and chronic disease portfolio.
The funding will also be used to construct a new 65,000m² multi-product manufacturing facility, designed with maximum flexibility to accommodate new processes and featuring an advanced working environment and technology.
The new facility will be future-proof and cost-effective, with a focus on optimal and compact process flows to reduce water and energy consumption.
Construction has already commenced, with API production expected to begin by early 2029.
The expansion project is anticipated to create 340 new jobs.
Novo Nordisk Product Supply, Quality and IT executive vice-president Henrik Wulff stated: “This important investment will ensure the continuous development of our late-phase pipeline into deliveries of important medicines for treatments to patients worldwide.
“The investment announced today confirms Hillerød and Denmark as cornerstones in our global footprint, and I would like to take this opportunity to thank the Danish government and parliament for their continued focus on ensuring good and stable infrastructure and supplies, allowing us to continue to expand our production capacity to the benefit of patients living with serious chronic diseases.”
Source: pharmaceutical-technology.com
After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.
SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.
After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.
